

Interferon- β 1a and SARS Coronavirus Replication

Lisa E. Hensley,* Elizabeth A. Fritz,* Peter B. Jahrling,* Christopher L. Karp,† John W. Huggins,* and Thomas W. Geisbert*

A global outbreak of severe acute respiratory syndrome (SARS) caused by a novel coronavirus began in March 2003. The rapid emergence of SARS and the substantial illness and death it caused have made it a critical public health issue. Because no effective treatments are available, an intensive effort is under way to identify and test promising antiviral drugs. Here, we report that recombinant human interferon- β 1a potentially inhibits SARS coronavirus replication in vitro.

The recent global outbreak of severe acute respiratory syndrome (SARS) has quickly gained notoriety as a newly emerging infectious disease. The etiologic agent was identified as a coronavirus (SARS-CoV) that is not closely related to any of the previously characterized coronaviruses (1,2). As of September 26, 2003, a total of 8,098 probable cases of SARS have occurred with 774 deaths.

No antiviral treatments are currently available against SARS-CoV. SARS cases have been treated symptomatically according to the severity of the illness. A treatment protocol consisting of antibacterial agents and a combination of ribavirin and methylprednisolone was recently proposed. However, the therapeutic value of ribavirin remains uncertain because it has no activity against SARS-CoV in vitro. Molecular modeling studies suggest that rhinovirus 3C^{pro} inhibitors may be useful for SARS therapy, but results of recent in vitro testing of the lead molecule, AG7088, were negative (3).

Previous studies showed that some coronaviruses, including avian infectious bronchitis virus, murine hepatitis virus, and human coronavirus 229E, are susceptible to type I interferons in vitro or in vivo (4–7). Therefore, we evaluated the in vitro efficacy of a recombinant human type I interferon (IFN), IFN- β 1a (Serono International, Geneva, Switzerland) against three different isolates of SARS-CoV (Tor2 and Tor7 and Urbani) using yield reduction assays. The IFN- β 1a preparation employed in this

study was selected because it is currently used as part of the most effective treatment regimen for relapsing forms of multiple sclerosis (8), and more importantly, because it was shown to have antiviral activity (as measured in a vesicular stomatitis virus cytopathic assay system) 14 times greater than the currently available treatment using IFN- β 1b (9).

In the current study, Vero E6 cells were treated with concentrations (5,000 to 500,000 IU/mL) of IFN- β 1a either 24 h before or 1 h after inoculation with the SARS-CoV (multiplicity of infection 0.1 PFU/cell), and monitored for cytopathic effect and production of infectious SARS-CoV at 24, 48, and 72 h postinfection. Inhibition of the SARS-CoVs by IFN- β 1a was dependent on both time of drug administration and time of culture sampling after SARS-CoV infection. Production of infectious SARS-CoV was potentially inhibited ($\geq 99.5\%$ or 2.00 log₁₀ PFU/mL) at 24 h postinfection by pretreatment of Vero E6 cells with IFN- β 1a at all concentrations tested (Figure 1). By 72 h postinfection, inhibition of SARS-CoV production by IFN- β 1a had declined for all three SARS-CoVs, with inhibition ($\geq 70\%$) being detected in the Tor7 (Figure 1) and Urbani isolates (data not shown). IFN- β 1a was somewhat less effective at inhibiting SARS-CoV replication when employed after infection of cultures (Figure 1). Nonetheless, production of infectious SARS-CoVs was considerably reduced ($\geq 90\%$ or 1.00 log₁₀ PFU/mL) at 24 and 48 h postinfection. Protection of Vero E6 monolayers against SARS-CoV-induced cytopathic effects by preinfection or postinfection treatment with IFN- β 1a was dramatic, even at 72 h postinfection (Figure 2). Additional concentrations of IFN- β 1a (0.5–5,000 IU/mL) were tested to determine the 50% inhibitory concentration (IC₅₀). Pretreatment of Vero E-6 cells with concentrations as low as 50 IU/mL, or posttreatment of cells with concentrations at 500 IU/mL, provided a 50% reduction with the Tor2 isolate at 24 h postinfection.

Faced with a burgeoning epidemic of SARS cases and a lack of effective treatment options, identifying compounds with antiviral activity that could be potential therapeutics has become a high priority. Our report suggests

*U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA; and †Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA

Report Documentation Page				Form Approved OMB No. 0704-0188	
Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to a penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.					
1. REPORT DATE 02 FEB 2004		2. REPORT TYPE N/A		3. DATES COVERED -	
4. TITLE AND SUBTITLE Interferon-beta 1a and SARS coronavirus replication, Emerging Infectious Diseases 10:317 - 319				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Hensley /LE Fritz, EA Jahrling, PB Geisbert, TW				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) United States Army Medical Research Institute of Infectious diseases, Fort Detrick, MD				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release, distribution unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT A global outbreak of severe acute respiratory syndrome (SARS) caused by a novel coronavirus began in March 2003. The rapid emergence of SARS and the substantial illness and death it caused have made it a critical public health issue. Because no effective treatments are available, an intensive effort is under way to identify and test promising antiviral drugs. Here, we report that recombinant human interferon-beta 1a potently inhibits SARS coronavirus replication in vitro.					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT SAR	18. NUMBER OF PAGES 3	19a. NAME OF RESPONSIBLE PERSON
a. REPORT unclassified	b. ABSTRACT unclassified	c. THIS PAGE unclassified			




Figure 1. Interferon (IFN)-β 1a inhibition of SARS-CoV replication in Vero E6 cells. Top panels, Vero E6 cells were incubated in the absence (-▲-) or presence of IFN-β 1a added 24 h before infection with the Tor2 (left) or Tor7 (right) isolate of SARS Co-V. Bottom panels, Vero E6 cells were incubated in the absence (-▲-) or presence of IFN-β 1a added 1 h after infection with the Tor2 (left) or Tor7 (right) isolate of SARS Co-V. Three concentrations of IFN-β 1a were employed for both studies: 5,000 IU/mL (-□-), 50,000 IU/mL (-■-), 500,000 IU/mL (-▲-). Samples of overlying media were collected at 24, 48, and 72 h postinfection and analyzed by plaque assay on Vero E6 cells.

that IFN-β 1a may be effective as a treatment for SARS-CoV infections. As noted above, IFN-β 1a is currently being used for a variety of clinical indications, including multiple sclerosis, and has shown dose-dependent efficacy in several clinical trials. Importantly, IFN-β 1a exhibited potent antiviral activity at doses that have already been shown to have acceptable safety profiles in animals (10). Thus, we report the identification of a compound that may

be suitable for rapid development as a treatment for SARS-CoV infection.

Acknowledgments

We thank Dr. Heinz Feldman for his kind provision of Tor2 and Tor7 isolates.

This study was supported, in part, by NIH grant R21 AI053539.

Dr. Hensley is a staff microbiologist in the Virology Division, United States Army Medical Research Institute of Infectious Diseases. She specializes in the pathogenesis and immunobiology of high-hazard virus infections in animal models for vaccine and antiviral drug development.

References

1. Peiris JSM, Lai ST, Poon LLM, Guan Y, Yam LY, Lim W, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. *Lancet* 2003; 361:1319–25.
2. Marra MA, Jones SJM, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YS, et al. The genome sequence of the SARS-associated coronavirus. *Science* 2003;300:1399–404.
3. Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. *Science* 2003;300:1763–7.
4. Sperber SJ, Hayden FG. Comparative susceptibility of respiratory viruses to recombinant interferons-alpha 2b and -beta. *J Interferon Res* 1989;9:285–93.




Figure 2. Interferon (IFN)-β 1a inhibition of SARS-CoV cytopathicity in Vero E6 cells. Vero E6 cells were infected with the Tor2 isolate of SARS-CoV and incubated for 72 h in the absence (left panel) or presence (right panel) of 500,000 IU of recombinant human IFN-β 1a. Cell rounding and detachment were prominent in the absence of IFN-β 1a. Minimal cell rounding or death was noted in the intact monolayer at 72 h postinoculation in the presence of IFN-β 1a (note: IFN-β 1a administered 1 h postinfection).

5. Pei J, Sekellick MJ, Marcus PI, Choi IS, Collisson EW. Chicken interferon type I inhibits infectious bronchitis virus replication and associated respiratory illness. *J Interferon Cytokine Res* 2001;21:1071-7.
6. Vassao RC, de Franco MT, Hartz D, Modolell M, Sippel AE, Pereira CA. Down-regulation of Bgpl(a) viral receptor by interferon-gamma is related to the antiviral state and resistance to mouse hepatitis virus 3 infection. *Virology* 2000;274:278-83.
7. Minagawa H, Takenaka A, Mohri S, Mori R. Protective effect of recombinant murine interferon beta against mouse hepatitis virus infection. *Antiviral Res* 1987;8:85-95.
8. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE trial. *Neurology* 2002; 59:1496-1506.
9. Antonetti F, Finocchiaro O, Mascia M, Terlizze MG, Jaber A. A comparison of the biologic activity of two recombinant IFN-beta preparations used in the treatment of relapsing-remitting multiple sclerosis. *J Interferon Cytokine Res* 2002;22:1181-1184.
10. Mager DE, Neuteboom B, Efthymiopoulos C, Munafo A, Jusko WJ. Receptor-mediated pharmacokinetics and pharmacodynamics of interferon- β 1a following intravenous and subcutaneous dosing in monkeys. *J Pharmacol Exp Ther* 2003;306:262-70.

Address for correspondence: Peter B. Jahrling, USAMRIID, Attn: MCMR-UIZ, 1425 Porter Street, Fort Detrick, MD 21702-5011, USA; fax: 301-619-4625; email: peter.jahrling@us.army.mil

EMERGING INFECTIOUS DISEASES

A Peer-Reviewed Journal Tracking and Analyzing Disease Trends

Vol.9, No.12, December 2003



Search past issues of EID at www.cdc.gov/eid



Disease emergence and control

